EGFR and neoplasm: Nevertheless, recent translational studies have shown that ICIs are more effective in patients with PD-L1 higher expression in tumor cells, a higher tumor mutation burden, or a higher density of tumor-infiltrating lymphocytes following EGFR TKI treatment (22–24).